The UK Court of Appeal has overturned a tribunal decision in the long-running Pfizer-Flynn antitrust case, according to a report by PYMNTS.com.

The dispute, one of the most protracted competition matters in recent UK enforcement history, centres on allegations relating to the pricing of a drug supplied by Pfizer and distributed by Flynn Pharma. The case has now returned a further twist with the appellate court's reversal of the earlier tribunal ruling.

What the Court Decided

The Court of Appeal set aside the decision issued by the lower tribunal, sending the matter in a new procedural direction. The appeals court concluded that the tribunal's earlier determination could not stand.

At this stage, the full text of the judgment and the precise grounds on which the Court of Appeal based its ruling have not been set out in the available reporting. Practitioners will need to review the formal judgment once published to assess the appellate court's reasoning in detail.

Background

The case stems from a Competition and Markets Authority (CMA) investigation into the pricing practices of Pfizer and Flynn Pharma. The regulator's findings were previously challenged before the tribunal, producing a decision that has now been overturned on appeal.

The litigation has drawn sustained attention from competition lawyers because it touches on questions of excessive pricing — an area of enforcement that remains contested and fact-sensitive in UK and EU competition law.

Practical Consequences for Practitioners

For competition counsel, the Court of Appeal's intervention underscores that findings in complex pricing cases remain vulnerable on appeal, and that parties facing adverse tribunal outcomes have realistic appellate prospects in this field. Companies under CMA investigation for pricing conduct, and their advisers, should track the formal judgment closely: the appellate court's reasoning on how pricing assessments are constructed will shape how the CMA frames future excessive-pricing cases and how respondents mount their defences. The decision also prolongs the lifecycle of a matter that has already run for years, meaning both pharmaceutical-sector clients and enforcement practitioners should prepare for continued uncertainty until the final position is resolved.

What Comes Next

The immediate consequence of the ruling is that the earlier tribunal decision no longer stands. The parties and the CMA must now consider the implications for any subsequent proceedings or potential further steps in the litigation.

Further reporting and the published judgment are expected to clarify the scope of the Court of Appeal's reasoning and its implications for the substance of the pricing allegations at the heart of the case.

This report is based on currently available information. Additional details will follow as the judgment becomes accessible.